Valuation: Cogent Biosciences, Inc.

Market Cap 6.4B 5.49B 5.12B 4.7B 8.84B 611B 8.98B 60.45B 23.67B 307B 24.02B 23.49B 1,014B P/E 2026 *
-16.4x
P/E 2027 * -35.2x
Enterprise Value 5.99B 5.14B 4.8B 4.4B 8.28B 573B 8.42B 56.65B 22.18B 287B 22.5B 22.01B 950B EV / Sales 2026 *
1,001x
EV / Sales 2027 * 21.6x
Free-Float
99.51%
Yield 2026 *
-
Yield 2027 * -
1 day-1.47%
1 week-5.46%
Current month-5.34%
1 month-5.71%
3 months+17.92%
6 months-3.89%
Current year+3.74%
1 week 36.57
Extreme 36.57
38.62
1 month 36.57
Extreme 36.57
43.39
Current year 30.87
Extreme 30.87
43.39
1 year 11.6
Extreme 11.6
43.73
3 years 3.67
Extreme 3.67
43.73
5 years 3.67
Extreme 3.67
43.73
10 years 3.67
Extreme 3.67
43.73
Manager TitleAgeSince
Chief Executive Officer 50 23/10/2020
Director of Finance/CFO 45 01/06/2018
Chief Tech/Sci/R&D Officer 52 06/04/2021
Director TitleAgeSince
Director/Board Member 68 01/02/2018
Director/Board Member 74 26/07/2019
Director/Board Member 59 26/07/2019
Date Insider Type Main position Quantity % Market Cap.
7/1/26 A Free

Director

627 0.0004%
6/9/26 A Free

Director

17,901 0.0105%
6/9/26 A Free

Director

17,901 0.0105%
Change 5-day change 1-year change 3-year change Capi.($)
-1.47%-5.46%+213.35%+215.50% 6.4B
-1.90%+3.12%+81.70%+110.88% 72.21B
-0.62%+15.62%+54.87%+91.23% 63.98B
+1.71%-1.22%+2.71%+501.29% 28.53B
+3.63%+8.57%+62.12%+24.72% 25.07B
+21.96%+21.98%+1.54%+2.50% 28.42B
-0.28%+6.02%+39.10%-13.95% 20.04B
0.00%-2.78%+247.46%+423.83% 18.19B
+1.81%+1.43%+23.67%+527.06% 15.96B
+2.39%+7.96%+44.96%+157.77% 13.48B
Average +2.72%+4.60%+77.15%+204.08% 29.23B
Weighted average by Cap. +2.17%+6.43%+64.06%+164.86%

Financials

2026 *2027 *
Net sales 5.99M 5.14M 4.8M 4.4M 8.28M 572M 8.41M 56.6M 22.16M 287M 22.49M 22M 949M 292M 250M 234M 214M 403M 27.9B 410M 2.76B 1.08B 13.99B 1.1B 1.07B 46.26B
Net income -405M -348M -325M -298M -560M -38.74B -569M -3.83B -1.5B -19.43B -1.52B -1.49B -64.24B -199M -171M -159M -146M -275M -19B -279M -1.88B -736M -9.53B -746M -730M -31.51B
Net Debt -403M -345M -323M -296M -556M -38.48B -566M -3.81B -1.49B -19.3B -1.51B -1.48B -63.82B -77.95M -66.87M -62.44M -57.29M -108M -7.45B -110M -737M -289M -3.74B -293M -286M -12.36B
Logo Cogent Biosciences, Inc.
Cogent Biosciences, Inc. is a clinical-stage biotechnology company. It is focused on developing precision therapies for genetically defined diseases. Its approach is to design rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its advanced program is bezuclastinib, also known as CGT9486, a highly selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis (SM), a serious and rare disease caused by unchecked proliferation of mast cells. The Company has on-going Phase I studies of its CNS-penetrant, selective mutant ErbB2 inhibitor and its potential best-in-class, wild-type-sparing, PI3Ka inhibitor. In addition, the Company’s research team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in KRAS and JAK2.
Employees
258
Date Price Change Volume
19/08/26 $36.85 -1.47% 1,249,799
18/08/26 $37.40 -1.24% 1,151,059
17/08/26 $37.87 -0.16% 1,595,174
14/08/26 $37.93 +1.66% 1,228,832
13/08/26 $37.31 -4.28% 1,414,240
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
36.85USD
Average target price
55.82USD
Spread / Average Target
+51.47%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. COGT Stock